Overview
The Emerging Science of Prophylactic Therapies for Migraine
Migraine Prevention: Highlights from a Live Symposium
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This activity relates to optimizing chronic migraine prevention via a review of key clinical trial data of CGRP monoclonal antibodies as well as tailoring the use of existing agents in complex patients to maximize function and minimize pain.
This activity is designed for clinicians involved in the care and treatment of patients with migraine pain.
Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment. However, studies have shown that of the 38% of patients who stand to benefit from prophylactic therapy, only 3-13% of them actually receive it. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are under clinical investigation and constitute a new prophylactic migraine therapy class. Increased physician attention when individualizing treatment plans to maximize therapy efficacy and minimize side effects as well as managing headache triggers and existing comorbidities continue to be vital strategies as new agents emerge and when maximizing patient function.
Upon completion of this activity, participants will be able to:
• Illustrate how to factor multiple patient-specific characteristics into the treatment plan when managing migraines.
• Examine and discuss the emerging science associated with calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) and their role in migraine prevention.
• Highlight strategies and tools to assess the impact of migraine on daily functioning and quality of life in order to generate a more personalized and inclusive treatment plan.
• Illustrate how to factor multiple patient-specific characteristics into the treatment plan when managing migraines.
• Examine and discuss the emerging science associated with calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) and their role in migraine prevention.
• Highlight strategies and tools to assess the impact of migraine on daily functioning and quality of life in order to generate a more personalized and inclusive treatment plan.
Welcome and Introductions
Fine-tuning the Treatment Plans of Chronic Migraine Patients
A Current and Emerging Therapies and Technologies
Assessing Disability and QoL in Patients with Migraines
Fine-tuning the Treatment Plans of Chronic Migraine Patients
A Current and Emerging Therapies and Technologies
Assessing Disability and QoL in Patients with Migraines
This activity is sponsored by ACHL.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher).
5. Adobe Reader to print certificate.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
David Dodick, MD, FAHS, FRCPC, FACP
Mayo Clinic
Phoenix, AZ
Deborah I. Friedman, MD, MPH, FAHS
University of Texas Southwestern Medical Center
Dallas, TX
Mayo Clinic
Phoenix, AZ
Deborah I. Friedman, MD, MPH, FAHS
University of Texas Southwestern Medical Center
Dallas, TX
Stewart J. Tepper, MD, FAHS
Geisel School of Medicine at Dartmouth
Hanover, NH
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest will be resolved prior to this CME/CE activity.
The following financial relationships have been provided:
David Dodick, MD, FAHS, FRCPC, FACP
Consulting Agreements: Alder Bio Pharmaceuticals Inc.; Allergan; Amgen; Autonomic Technologies; Boston Scientific; Dr. Reddy’s Laboratories Ltd.; Eli Lilly and Company; eNeura, Inc.; INSYS Therapeutics; Teva Pharmaceutical Industries Ltd.; Trigemina, Inc.; Xenon Pharmaceuticals Inc, Zosano
Options: EPIEN Medical, Inc.; Second Opinion, Inc.; Xalan, LLC/GBS Ventures
Patent holder: Allergan PREEMPT injection paradigm
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Deborah I. Friedman, MD, MPH, FAHS
Advisor: Alder BioPharmaceuticals, Avanir, Supernus, Teva, Zosano
Funding for Research/Clinical Trials: Autonomic Technologies, Inc., Merck
Consulting Agreements: Allergan, Avanir, Eli Lilly
Speakers' Bureau: Allergan, Avanir, Teva
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Stewart J. Tepper, MD, FAHS
Advisor: Acorda, Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s, Electrocore, eNeura, Kimberly-Clark, Pernix, Pfizer, Scion Neurostim, Supernus, Teva, Zosano
Royalty Recipient: Springer
Funding for Research/Clinical Trials: Alder, Allergan, Amgen, ATI, Avanir, Electrocore, eNeura, Scion Neurostim, Teva, Zosano
Stockholder: ATI
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Discussion may include therapies/devices either currently under clinical investigation or not approved in the US.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online webinar and complete the post-test and evaluation forms. To receive credit, 66% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate. Inquiries may be directed to ACHL at (877) 444-8435, ext. 205.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
